European LeukemiaNet criteria for failure or suboptimal response reliably identify patients with CML in early chronic phase treated with imatinib whose eventual …
D Marin, D Milojkovic, E Olavarria… - Blood, The Journal …, 2008 - ashpublications.org
The majority of patients with chronic myeloid leukemia in chronic phase gain substantial
benefit from imatinib but some fail to respond or lose their initial response. In 2006, the …
benefit from imatinib but some fail to respond or lose their initial response. In 2006, the …
[HTML][HTML] European LeukemiaNet criteria for failure or suboptimal response reliably identify patients with CML in early chronic phase treated with imatinib whose …
D Marin, D Milojkovic, E Olavarria, JS Khorashad… - Blood, 2008 - ncbi.nlm.nih.gov
The majority of patients with chronic myeloid leukemia in chronic phase gain substantial
benefit from imatinib but some fail to respond or lose their initial response. In 2006, the …
benefit from imatinib but some fail to respond or lose their initial response. In 2006, the …
European LeukemiaNet criteria for failure or suboptimal response reliably identify patients with CML in early chronic phase treated with imatinib whose eventual …
D Marin, D Milojkovic, E Olavarria, JS Khorashad… - …, 2008 - pubmed.ncbi.nlm.nih.gov
The majority of patients with chronic myeloid leukemia in chronic phase gain substantial
benefit from imatinib but some fail to respond or lose their initial response. In 2006, the …
benefit from imatinib but some fail to respond or lose their initial response. In 2006, the …
European LeukemiaNet criteria for failure or suboptimal response reliably identify patients with CML in early chronic phase treated with imatinib whose eventual …
D Marin, D Milojkovic, E Olavarria, JS Khorashad… - Blood, 2008 - europepmc.org
The majority of patients with chronic myeloid leukemia in chronic phase gain substantial
benefit from imatinib but some fail to respond or lose their initial response. In 2006, the …
benefit from imatinib but some fail to respond or lose their initial response. In 2006, the …
European LeukemiaNet criteria for failure or suboptimal response reliably identify patients with CML in early chronic phase treated with imatinib whose eventual …
D Marin, D Milojkovic, E Olavaria - leukemia-cell.org
Úvod: Většina pacientů s chronickou myeloidní leukémií v chronické fázi (CML-CP) profituje
z léčby imatinibem. Někteří však na léčbu neodpovídají nebo ztrácí prvotní odpověď. V roce …
z léčby imatinibem. Někteří však na léčbu neodpovídají nebo ztrácí prvotní odpověď. V roce …
[HTML][HTML] European LeukemiaNet criteria for failure or suboptimal response reliably identify patients with CML in early chronic phase treated with imatinib whose …
D Marin, D Milojkovic, E Olavarria, JS Khorashad… - Blood, 2008 - Elsevier
The majority of patients with chronic myeloid leukemia in chronic phase gain substantial
benefit from imatinib but some fail to respond or lose their initial response. In 2006, the …
benefit from imatinib but some fail to respond or lose their initial response. In 2006, the …
European LeukemiaNet criteria for failure or suboptimal response reliably identify patients with CML in early chronic phase treated with imatinib whose eventual …
D Marin, D Milojkovic, E Olavarria, JS Khorashad… - Blood, 2008 - kclpure.kcl.ac.uk
The majority of patients with chronic myeloid leukemia in chronic phase gain substantial
benefit from imatinib but some fail to respond or lose their initial response. In 2006, the …
benefit from imatinib but some fail to respond or lose their initial response. In 2006, the …
[PDF][PDF] European LeukemiaNet criteria for failure or suboptimal response reliably identify patients with CML in early chronic phase treated with imatinib whose eventual …
D Marin, D Milojkovic, E Olavarria, JS Khorashad… - BLOOD, 2008 - academia.edu
The majority of patients with chronic myeloid leukemia in chronic phase gain substantial
benefit from imatinib but some fail to respond or lose their initial response. In 2006, the …
benefit from imatinib but some fail to respond or lose their initial response. In 2006, the …
[引用][C] European LeukemiaNet criteria for failure or suboptimal response reliably identify patients with CML in early chronic phase treated with imatinib whose eventual …
D MARIN, D MILOJKOVIC, J PAVLU, M KLAMMER… - Blood, 2008 - pascal-francis.inist.fr
European LeukemiaNet criteria for failure or suboptimal response reliably identify patients
with CML in early chronic phase treated with imatinib whose eventual outcome is poor CNRS …
with CML in early chronic phase treated with imatinib whose eventual outcome is poor CNRS …
European LeukemiaNet criteria for failure or suboptimal response reliably identify patients with CML in early chronic phase treated with imatinib whose eventual …
D Marin, D Milojkovic, E Olavarria, JS Khorashad… - Blood, 2008 - cir.nii.ac.jp
抄録< jats: title> Abstract</jats: title>< jats: p> The majority of patients with chronic myeloid
leukemia in chronic phase gain substantial benefit from imatinib but some fail to respond or …
leukemia in chronic phase gain substantial benefit from imatinib but some fail to respond or …